APVO Form 4: SVP/CFO Daphne Taylor Receives 11,500 RSUs—Vests in One Year

Rhea-AI Filing Summary

Aptevo Therapeutics Inc. (APVO) reports that Daphne Taylor, the company's SVP and Chief Financial Officer, acquired 11,500 Restricted Stock Units (RSUs) on 08/06/2025. The filing shows these RSUs convert one-for-one into common stock and are recorded as a direct holding following the reported transaction.

The RSUs carry a $0 price in the filing and vest in full on the first anniversary of the grant, meaning they will convert into 11,500 common shares when vested. The form reflects an insider equity grant reported under Form 4 and does not disclose the company’s total outstanding shares, so the percentage dilution from this grant cannot be determined from this filing alone.

Positive

• 11,500 RSUs were granted to the SVP/CFO and are documented transparently in a Form 4 filing.
• Vesting schedule is explicit: the RSUs vest in full on the first anniversary of the grant, providing clear timing for conversion.

Negative

• RSUs listed at $0 will convert into 11,500 common shares upon vesting, increasing the share count when they vest.
• Materiality cannot be assessed from this filing because it does not disclose total outstanding shares or the reporting person's prior holdings.

Insights

Corporate Governance Expert

TL;DR: Executive received 11,500 RSUs that vest in one year; routine equity grant with clear vesting but limited immediate disclosure on materiality.

The Form 4 documents a direct acquisition of 11,500 RSUs by Daphne Taylor, SVP and CFO, converting one-for-one into common stock. The grant is structured with a single-date full-vesting schedule (vests in full on the first anniversary of grant), which provides straightforward alignment of executive and shareholder timing but also creates a defined future issuance event. The filing includes the $0 price characteristic of RSUs and an attorney-in-fact signature; it does not provide information on outstanding share count or prior holdings for Taylor, so governance impact is limited to disclosure of the award rather than showing material ownership change.

Securities Analyst

TL;DR: The RSU grant creates potential conversion into 11,500 shares; without outstanding share data the market impact cannot be quantified from this filing.

This Form 4 reports an acquisition of 11,500 derivative securities (Restricted Stock Units) that will convert to 11,500 shares of common stock when vested. The instrument carries a $0 conversion price and is held directly. From a securities perspective the event is an issuance over time rather than a sale by the insider. The filing lacks context on total shares outstanding and any prior insider holdings, so the size of this grant relative to market capitalization or float is not determinable here, limiting any assessment of dilution or market impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Daphne

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CFO

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2025		A		11,500		(2)	(2)	Common Stock	11,500	$0	11,500	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. The RSUs vest in full on the first anniversary of the date of grant.

	/s/ SoYoung Kwon, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Daphne Taylor (APVO) acquire according to the Form 4?

The filing shows Daphne Taylor acquired 11,500 Restricted Stock Units (RSUs) that convert one-for-one into common stock.

What is Daphne Taylor's position at Aptevo (APVO)?

The form identifies the reporting person as an Officer with title SVP, CFO.

When do the RSUs vest and convert to common stock?

The RSUs vest in full on the first anniversary of the date of grant and convert one-for-one into common stock upon vesting.

Did the reporting person pay for the RSUs?

The filing lists a $0 price for the RSUs, consistent with restricted stock unit awards rather than a cash purchase.

How many common shares will the RSUs convert into?

The RSUs convert one-for-one, so the grant will convert into 11,500 common shares upon vesting.